Homologous recombination (HR) is a strategy for genetic correction. The efficiency of HR can be increased by creating a targeted double-strand break (DSB) via zinc-finger nucleases (ZFNs) and/or by introducing linear donor DNA intracellularly. Some studies have suggested that increased copy numbers of linear donor DNA may further improve HR efficiency. However, the introduction of multiple copies of a linear donor fragment remains a challenge, particularly in cell types with low transfection efficiency. In this study, we developed a vector that carries tandem repeats of a donor fragment, with each repeat flanked by ZFN target sequence fragments (TSFs). The cleavage of the flanking TSF sequence by ZFN would lead to the release of multiple linear fragment. We demonstrated that this novel vector carrying five copies of a linearizable donor fragment, when co-transfected with a ZFN-expressing vector in 293 cells, showed improved HR efficiency about 30 times, as compared with vector carry nonlinearizable donor. For the application of gene therapy, we then introduced this system into an adenoviral vector, which also revealed markedly improved ZFN-mediated HR efficiency in cells. The novel strategies presented here have the potential to promote the application of ZFNs in both basic research and disease therapy.
INTRODUCTION
Targeted genetic correction by homologous recombination (HR) between donor DNA and a mutated locus is a novel and interesting approach for gene therapy. This approach can permanently reverse genetic disorders and allow the production of normal proteins via the endogenous regulatory signals of the cell. Moreover, it can prevent harmful insertional mutagenesis.
HR, as a natural mechanism, typically occurs in mammalian cells at a frequency of only about 1 for each 10 6 cells treated, which has made clinical application impossible. 1, 2 However, the following two conditions could increase its efficiency: (1) creating a targeted double-strand break (DSB) [3] [4] [5] [6] [7] [8] [9] and (2) introducing multiple copies of homologous linear 'donor' DNA into cells. 10, 11 The DSB can be induced by a zinc-finger nuclease (ZFN), which is a designed, sequence-specific endonuclease that can be customized to cleave a user-chosen DNA target-in this case, a mutated locus. Researchers are actively developing new and effective ways to induce targeted DSBs. Although TALENs (transcription activator-like effector nucleases) [12] [13] [14] [15] and CRISPR (clustered regularly interspaced short palindromic repeats)/Cas (CRISPR-associated) [16] [17] [18] [19] have been recently presented as promising tools for DSB induction, research into how to improve the intracellular introduction of linear donor DNA fragments lags behind. Earlier studies showed that the linear donor DNA, usually produced by PCR, could be introduced into cells by transfection or microinjection to improve gene-targeting frequency. 10, 20 Then, a system was described in Drosophila for the intracellular production of linear donor fragments by inducing a DSB at each end of the homologous sequence. 21 These linear fragments were 'ends-out' vectors that could be used for gene replacement. To generate in vivo linear DNA for mammalian cells, de Pié doue et al. 22 set up a two-vector system for the intracellular release of linear fragments from circular plasmids with I-SceI. However, it remains to be determined whether this system could be effective for targeting genomic DNA in primary cells.
In this study, by combining the advantages of different systems, we have developed a novel vector that carries tandem repeats of a donor fragment, with each repeat being flanked by ZFN target sequence fragments (TSFs). This vector releases multiple copies of a linear donor fragment in the presence of a ZFN intracellularly, which also generates a targeted DSB in the genome. We demonstrated that the novel system could improve the efficiency of ZFN-mediated HR. We also successfully introduced this system into an adenoviral vector to make it useful for gene therapy.
RESULTS
Improved efficiency of ZFN-mediated HR by a single-plasmid vector carrying multiple copies of a linearizable donor fragment To test our hypothesis that multiple copies of a linear donor DNA fragment released intracellularly from a single vector could improve HR efficiency, we constructed a plasmid vector system carrying tandem repeats of a donor fragment. Each fragment, 1 kb in length, was flanked by human AAVS1 TSF. Being co-transfected with an AAVS1 ZFN-expressing vector, the plasmids would be linearized and multiple copies of a donor fragment would be released, as illustrated in Figure 1 .
We then took advantage of a luciferase gene-based reporter system (293-luci2-AAVS1 TSF) 23 -a cell line with a chromosomally integrated mutated luciferase produced by inserting a human AAVS1 TSF into a luciferase sequence-to examine whether the intracellular release of multiple copies of a linear donor fragment could improve the efficiency of ZFN-mediated HR. 293-luci2-AAVS1 TSF cells 23 were co-transfected with a vector expressing ZFN against human AAVS1 and a plasmid carrying a single copy/ tandem repeats of linearizable donor fragment (that is, each luciferase fragment, named luci2, is flanked by AAVS1 TSF) or a control plasmid carrying a single copy/tandem repeats of nonlinearizable donor fragment.
On the basis of relative luciferase activity, the HR efficiency of the vector that released one copy of linear donor fragment was about 10 times higher than that of the vectors that carry either a single copy or tandem repeats of nonlinearizable donor fragment in the presence of AAVS1 ZFN (Figure 2a) . The vector carrying five copies of linearizable donor fragment was 30 times more efficient than the one carrying nonlinearizable donor in the presence of AAVS1 ZFN (Figure 2a ). When five times the amount of the vector carrying one copy of a linearizable donor was applied to increase the copy number of donor fragment, the HR efficiency of this vector showed no significant improvement, for unknown reasons, and was still significantly lower than that of the vector carrying five copies of linearizable donor (Supplementary Figure S1 ). In addition, we noticed that the transfection efficiency could be saturated and the HR efficiency decreased, when the amount of plasmid carrying one copy of linear donor exceeded the suggested maximum dose of Lipofectamine 2000 transfection system (Invitrogen, Carlsbad, CA, USA). To test whether the efficiency of ZFN-mediated HR is correlated with the copy numbers of donor fragment, we co-transfected AAVS1 ZFNexpressing vector with a vector carrying different copy numbers of linearizable donor fragment into the 293-luci2-AAVS1 TSF cell line. As the copy number of donor fragment increased, the HR efficiency gradually improved, peaking when the copy number reached six, and then decreasing when the copy number was more than six ( Figure 2b ). It was noteworthy that there was a difference between the values of vector carrying five copies of donor in Figures 2a and b , which was possibly due to some technique problems, including the different amount of internal reference applied. In the presence of the same amount of AAVS1 ZFN expression, with the increase in the amount of vector carrying one copy of a linear donor fragment, HR efficiency increased linearly; however, with the increase of the amount of vector carrying six copies of linear donor fragment, HR efficiency first increased and then decreased, suggesting a possible relative insufficiency of AAVS1 ZFN and the resultant inadequate release of linear donor fragments (Figure 2c ). de Pié doue et al. 22 showed that the homologous sequence had to be more than 200 bp long to show significant improvement, if the donor was linearized by I-SceI. In this study, when being co-transfected with AAVS1 ZFNexpressing vector, the vector carrying multiple copies of a linearizable donor fragment with a length of 100 bp (luci2 50arm) showed significantly improved HR efficiency compared with control vector. However, the HR efficiency of vectors carrying multiple copies of a linearizable donor DNA with a length of 1 kb was still higher (Figure 2d ). The intracellular release of linear donor fragments was confirmed by Southern blot in the cells cotransfected by AAVS1 ZFN-expressing plasmids and the vector carrying multiple copies of a linearizable donor fragment ( Figure 2e ).
We next tested this system on an endogenous gene, AAVS1. Similarly, a plasmid carrying multiple copies of the AAVS1 donor fragment was constructed. Each AAVS1 donor fragment (AAVS1 500arm) was composed of a pair of 500 bp up and down homologous arms, between which a ClaI enzyme site was inserted (Figure 3a) , and each fragment was flanked with AAVS1 TSFs. HEK293 cells were co-transfected with a plasmid carrying four copies of AAVS1 donor fragment and an AAVS1 ZFN-expressing vector. The stable integration of the ClaI restriction site, which is indicative of homology-directed repair, was observed in 6.5% of alleles determined by Southern blot analysis. The targeted integration was only observed in 3 or 0% of alleles of HEK293 cells treated with plasmids carrying one copy of linearizable donor DNA or nonlinearizable donor DNA, respectively ( Figure 3b ).
Efficient ZFN-mediated HR by adenoviral vector carrying multiple copies of donor fragment To make it useful for gene therapy, we then introduced this system into adenovirus (Ad), which is a naturally linearized vector that can provide great quantities of extrachromosomal donor DNA. A U87 cell line carrying a chromosomally integrated luciferase gene-based reporter system (named U87-luci2-AAVS1 TSF) was co-infected with ZFN-expressing Ad and different donorcarrying Ad. It was shown that the HR efficiency, quantified by relative luciferase activity, was significantly higher in U87 cells Figure 1 . Cartoon of the vector carrying multiple copies of a linear donor fragment. The plasmid carries tandem repeats of the donor fragment, with each fragment being flanked by AAVS1 TSF. When co-transfected with a ZFN-expressing vector, the plasmids can be linearized and multiple copies of the linear donor fragment can be released.
Vector with multiple-copy donor for genome editing W Zhang et al (Figure 4a ). As expected, the luciferase activity could be improved by increasing the multiplicity of infection of the virus. Interestingly, HR efficiency was higher in cells treated with Ad carrying one copy of linearizable donor fragment than in cells treated with Ad carrying one copy of nonlinearizable donor fragment, although donor DNA carried by Ad is naturally linearized. This Ad system was also tested on the endogenous gene human AAVS1 (Figure 4b ). U2-OS cells were co-infected by an Ad carrying AAVS1 donor DNA (see Figure 3a) and an Ad expressing AAVS1 ZFN. The integration of the ClaI restriction site, determined by Southern blot analysis, was observed in about 12, 4.1 and 0.7% of alleles in U2-OS cells treated with Ad carrying four copies of a linearizable donor fragments, one copy of a linearizable donor fragment and one copy of a nonlinearizable donor fragment, respectively.
DISCUSSION
In this study, we developed a plasmid vector carrying tandem repeats of a donor fragment with each repeat flanked by ZFN TSFs. We demonstrated that the novel system, when coadministered with a ZFN-expressing vector, could improve the efficiency of ZFN-mediated HR. We then successfully introduced this system into an adenoviral vector. The introduction of multiple copies of homologous linear donor DNA fragments into cells is an alternative strategy to improve ZFN-mediated HR efficiency besides creating a DSB in the target DNA. As chemical transfection of long linear fragments is not efficient, microinjection was applied to avoid this limitation. Successful microinjection of small DNA fragments has previously been demonstrated in the conversion of a normal b-globin locus to a sickle cell disease genotype of progenitor hematopoietic cells. Vector with multiple-copy donor for genome editing W Zhang et al However, automation of microinjection is difficult for routine use and is well adapted only for individual adherent cells. de Piédoue et al. 22 set up a two-vector system for the intracellular release of linear fragments from circular plasmids with I-Sce I, which showed enhanced correction of an extrachromosomal mutated gfp target by at least 10 times. By using the same ZFN to release multiple copies of a linear donor fragment intracellularly and to induce targeted DSB in the genome, our system successfully demonstrated improved efficiency of HR-based targeted genetic modification, as compared with the control, the single-donor system, the latter of which showed an overall HR efficiency similar to that reported elsewhere. 24, 25 Previous studies demonstrated that the length of the homologous arm had an impact on HR efficiency. [26] [27] [28] [29] [30] Feugeas's group showed that the homologous sequence had to be more than 100 bp long to show clear-cut HR improvement and should be more than 200 bp long to show significant improvement, if the donor was linearized by I-SceI. 22 In this study, linearized donor fragments of 100 bp revealed good HR efficiency, which was significantly higher than that of a nonlinearized donor of similar length. The improved HR might be because of the co-cleavage of chromosome and targeting vector. Similarly, co-cleavage of the chromosome and transgene-containing donor by ZFN has also been shown to improve gene integrations. 31 ZFN-mediated HR efficiency would be saturated when the length of a homologous arm reached 1 kb. 25 Therefore, it is probably a better approach to improve HR by using tandem repeats of a donor fragment than by using one long, single-copy donor sequence.
Ad is among the most commonly used vectors for gene therapy. As a naturally linearized vector, Ad is a good delivery vehicle for linear donor fragments to improve the efficiency of ZFN-mediated HR. Theoretically, the donor expressed by Ad should be linearized; however, we observed that the cleavage and linearization of donor-carrying Ad by ZFN could further improve the HR efficiency, which might be related to the decreased reclosure of the Ad genome mediated by terminal proteins. Consistent with previous observations, [32] [33] [34] this study showed that HR efficiency could also be improved simply by increasing the amount of donor-carrying vector (either plasmid or Ad). However, for the purpose of gene therapy, it would be beneficial to use lower amounts of the vector that carries multiple copies of linear donor fragment, to improve HR efficiency while avoiding cytotoxicity. The system described in this paper can be further optimized. It has been reported that the Ad's early proteins could inhibit HR efficiency. 35 Therefore, we expect that construction of a gutless Ad, which has minimal expression of Ad early proteins, will improve the HR efficiency of this system. Our additional future studies will also include testing our system in AAV or nonintegrating lentivirus, combining our system with TALENs and CRISPR/Cas, which are new promising tools to induce DSBs that are relatively easier to develop than ZFNs, and testing our system in animal tissues or in stem cells.
In conclusion, our novel system could be applied to cells with low transfection effectiveness to increase ZFN-mediated HR efficiency, facilitating the application of ZFN in both basic research and genetic disease therapy.
MATERIALS AND METHODS

Cell culture
HEK293, HEK293T, U2-OS and U87 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA), cultured in 10% Dulbecco's modified Eagle medium (high glucose; Invitrogen) containing 10% newborn calf serum. 293-luci2-AAVS1 TSF were kept in the lab. 23 The U87-luci2-AAVS1 TSF cell line was established according to a previous method. 23 In brief, the lentivirus was produced in HEK293T cells and the supernatant was used to infect U87 cells, followed by positively or negatively screening in the presence of a selection medium containing G418 (200 mg ml À 1 ). The selection medium was changed every 2 days.
Plasmid construction ZFN expression vector. AAVS1 ZFNs and hPGRN ZFNs were synthesized according to the sequence reported previously. 36,37 AAVS1 ZFNs were used in their obligate heterodimer, high-fidelity FokI 38 form, cloned into Ad E3 shuttle vector pE3 as a 2A fusion construct, which was driven by cytomegalovirus.
Donor vector. A 1-kb luciferase fragment (using luci2 from pGL4 vector as a template, named luci2F) was amplified using the following primers as donors to correct mutant luciferase gene (luci21000F SalI for: 5 0 -AGTCGACTCGGATCGTGGTGTGCAG-3 0 ; luci21000F BglII-XhoI reverse: 5 0 -AAGATCTTTCTCGAGTCGGGGTTGTTAACGTAG-3 0 ) and then cloned into Ad E1 shuttle vector, pE1 shuttle, to get pE1/1 Â luci2F. pE1/luci2 50arm was obtained using the same method, using the following primers: luci2 50arm SalI for 5 0 -GCGACCCCATCTTCGGCAACC-3 0 ; luci2 500arm BglII-XhoI reverse: 5 0 -AAGATCTTTCTCGAGAAGTAGCCCAGCGTGGT-3 0 . AAVS1 up and down homologous arms were amplified from human genome DNA using the following primers: (AAVS1 up
0 -AAGATCTTTCTCGAGcagccctgccaggacggg-3 0 ), and then both were inserted into Ad E1 shuttle vector pE1 to get pE1/AAVS1 500arm; a ClaI site was introduced between the up and down homologous arm. AAVS1 TSF was obtained by annealing of primers (AAVS1 TSF SXBL for 5
0 -TCGACcaccccacagtggggccactagggacaggattCTCGAGGGATCCA-3 0 ; AAVS1 TSF SXBL reverse 5 0 -GATCTGGATCCCTCGAGaatcctgtccctagtggccc cactgtggggtgG-3 0 ). To obtain multiple luciferase donor vectors, AAVS1 TSF was first inserted into pE1 through SalI and BglII to get pE1/AAVS1 TSF, while a XhoI site was introduced at the 3 0 terminal of AAVS1 TSF. Then, a luci2F fragment was cut by SalI and BglII and inserted into pE1/AAVS1 TSF through XhoI and BglII site to get pE1/1 Â AAVS1 TSF luci2F; at the same time a XhoI was introduced at the 3 0 terminal of luci2F. AAVS1 TSF luci2F was cut from pE1/1 Â AAVS1 TSF luci2F by SalI and BglII and ligated with pE1/1 Â AAVS1 TSF luci2F vector, which was cut by XhoI and BglII site to get pE1/2 Â AAVS1 TSF luci2F. This step was repeated to produce vectors carrying different numbers of donor fragments. Vectors carrying multiple luci2F fragments that were not flanked by AAVS1 TSF, pE1/5 Â luci2F, were constructed via the same process. Vectors carrying multiple AAVS1-500arms were constructed using the same method as the vectors carrying multiple luci2F fragments.
Lentivirus vector. The 700-bp luciferase N-terminal fragment, which is ended with TAA in frame with the open reading form of luciferase to disrupt the expression of functional luciferase, and 1 kb luciferase C-terminal fragment were amplified and cloned into pLenti/mcherry-T2A-neomycin. Then, the AAVS1 TSF was inserted between them to get pLenti/ luciferase-AAVS1 TSF/mcherry-T2A-neomycin. The pLenti/luciferase-AAVS1 TSF/mcherry-T2A-neomycin vector was used to build the U87-luci2-AAVS1 TSF cell line.
Ad construction. The Ad E3 shuttle vector carrying AAVS1 ZFN was cut by PacI and was homologous to the Ad backbone vector, cut by the SwaI enzyme to produce pAd5-AAVS1 ZFN. Then, the Ad E1 shuttle vector carrying an eGFP expression cassette was cut by ScaI and homologous to pAd5-AAVS1 ZFN, which was cut by PmeI to get pAd5-AAVS1 ZFN-eGFP. The Ad E1 shuttle vector carrying a single luci2F fragment or multiple luci2F fragments was cut by PacI and homologous to the Ad backbone vector, which was cut by PacI in 293 cells to obtain Ad carrying a single or multiple luci2F fragments. Ad carrying a single or multiple AAVS1 500arm fragments was constructed the same way. Ads were produced and purified according to previous methods. 39 Luciferase correction assay 293-luci2-AAVS1 TSF cells (4 Â 10 5 ) were plated on a 24-well plate 1 day before transfection. Donor plasmid and ZFN expression plasmid were transfected. Renilla luciferase was transfected as an internal reference. Ninety-six hours post transfection, cells were collected and the cell lysate was used to analyze the activity of luciferase using a Dual Luciferase Assay Kit (Promega, Madison, WI, USA).
U87-luci2-AAVS1 TSF cells (4 Â 10 5 ) were plated on a 24-well plate 1 day before infection. Ad carrying AAVS1 ZFN and Ad carrying different donor fragments were used to co-infect U87-luci2-AAVS1 TSF cells at indicated multiplicity of infection. Ninety-six hours post infection, cells were Vector with multiple-copy donor for genome editing W Zhang et al collected and cell lysates were used to analyze luciferase activity using a Luciferase Assay Kit (Promega).
Endogenous gene targeting in vitro
Genome targeting in HEK293 cells. HEK293 cells were collected using 0.25% trypsin/EDTA solution (Invitrogen) and 2 Â 10 6 cells, resuspended in phosphate-buffered saline, were electroporated with donor plasmids and AAVS1 ZFN-encoding plasmid using a Gene Pulser Xcell System (Bio-Rad, Hercules, CA, USA). Four days after transfection, cells were collected and genome DNA was extracted for gene-targeting assay.
Gene targeting in U2-OS cells. U2-OS cells (1 Â 10 6 ) were plated on a 60-mm plate and infected by Ad with indicated multiplicity of infection. Four days after infection, cells were collected and genome DNA was extracted for gene-targeting assay.
Gene-targeting efficiency assay
Genomic DNA was extracted from HEK293 cells or U2-OS cells using a TIANamp Genomic DNA Kit (TIANGEN Biotech, Beijing, China). The AAVS1 locus was amplified by PCR in the presence of dNTPs, using the AAVS1 forward (5 0 -GGCCCTGGCCATTGTCACTT-3 0 ) and AAVS1 reverse (5 0 -GGAACGGGGCTCAGTCTG-3 0 ) primers and then the PCR product was used as a template for nest PCR using the AAVS1 nest forward (5 0 -GCTGCACCACGTGATGTCCT-3 0 ) and AAVS1 nest reverse (5 0 -CACAAAGG GAGTTTTCCACACG-3 0 ) primers. The primers were located outside the donor fragment. The PCR products were then purified with an AxyPrep DNA Gel Extraction Kit (Axygen, Hangzhou, China), digested with ClaI, resolved by DNA gel electrophoresis and detected using Southern blot. All PCR reactions were performed using LA Taq (Takara, Dalian, China).
Detection of cleaved donor fragments released in situ
The 293 cells (2 Â 10 6 ) were transfected with 10 mg of pE1/2 Â AAVS1 TSF luci2F and 5 mg of pE3/AAVS1 ZFN using Lipofectamine 2000 Transfection Reagent (Invitrogen). Twenty-four hours post transfection, cells were collected and genome DNA was extracted using a TIANamp Genomic DNA Kit (TIANGEN Biotech) followed by Southern blot detection.
Southern blot
Evaluation of the release of linear donor fragments. Luciferase DNA probes were amplified from luciferase gene with LA Taq DNA polymerases (Takara) using the following primers: luci2 probe forward 5 0 -TCGGATCGTGGTGTG CAG-3 0 and luci2 probe backward 5 0 -GCTGAGGATAGCGGTGTCGG-3 0 , and were then labeled with Biotin using the Biotin Decalabel DNA Labeling Kit (Fermentas, Hunover, MD, USA). Twenty micrograms of genomic DNA was concentrated by precipitation, electrophoresed on agarose gels (0.8%) and transferred to hybond-N þ membrane (Amersham Biosciences, Piscataway, NJ, USA). After hybridization at 42 1C overnight, the membrane was washed and developed using a Biotin Chromogenic Detection Kit (Fermentas), following the manufacturer's instructions.
AAVS1 locus targeting efficiency assay. AAVS1 probe was amplified from human genome DNA using the following primers: AAVS1 probe forward 5 0 -CTTCACTCGCTGGGTTCC-3 0 and AAVS1 probe backward 5 0 -GGAGGGGA CAGATAAAAG-3 0 , and were then labeled with Biotin using the Biotin Decalabel DNA Labeling Kit (Fermentas). The ClaI assay result was resolved by DNA gel electrophoresis and transferred to hybond-N þ membrane (Amersham Biosciences). After hybridization at 42 1C overnight, the membrane was washed and developed using a Biotin Chromogenic Detection Kit (Fermentas), following the manufacturer's instructions.
